Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high plasma homocysteine in chronic hepatitis C (CHC) infected patients from the Northeast of Brazil

Nutrition Journal

Volumn 10, Issue 1, 2011, Pages

  Siqueira, Erika Rf ^a,b,c   Oliveira, Cláudia Pms ^a   Muniz, Maria Tc ^b   Silva, Filipe ^b   Pereira, Leila Mmb ^b,c   Carrilho, Flair J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c Ipojuca   (Brazil)

Author keywords

Genotype 1; Hepatitis C; Homocysteine; MTHFR; Steatosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); GENOMIC DNA; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD; BRAZIL; CHEMOLUMINESCENCE; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STEATOSIS; CROSS-SECTIONAL STUDY; GENETIC POLYMORPHISM; GENETICS; HYPERHOMOCYSTEINEMIA; MIDDLE AGED; PATHOLOGY;

HEPATITIS C VIRUS;

BRAZIL; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 80051796908     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-10-86     Document Type: Article

References (47)

1. Homocysteine and cardiovascular disease. Refsun H, Ueland P, Nygard O, Vollset SE, Annu Rev Med 1998 49 31 62 (Pubitemid 28197439)
2. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerosis outcomes. Bostom AG, Lathrop L, Kidney Int 1997 52 10 20 10.1038/ki.1997.298 9211341 (Pubitemid 27321809)
3. Open or closed? A word of differences: A history of homocysteine research. Eskes TKAB, Nutr Rev 1998 56 236 244 9735677 (Pubitemid 28419771)
4. Identification of cognitive impairment in the elderly: Homocysteine is an early marker. Lehmann M, Gottfries CG, Regland B, Dementia 1999 10 12 20 (Pubitemid 28567038)
5. Betaine decreases hyperyhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Ji C, Kaplowitz N, Gastroenterology 2003 124 1488 1499 10.1016/S0016-5085(03)00276-2 12730887 (Pubitemid 36531821)
6. Human methylenetetrahydro folate reductase: isolation of cDNA, mapping and mutation identification. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R, Nat Gen 1994 7 195 200 10.1038/ng0694-195 (Pubitemid 24174661)
7. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Van der Put NMJ, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ, Am J HumGenet 1998 62 1044 1051 10.1086/301825 9545395 (Pubitemid 28199004)
8. Methylenetetrahydro folate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. Andreassi MG, Botto N, Battaglia D, Antonioli E, Masetti S, Manfredi S, Colombo MG, Biagini A, Clerico A, HumGenet 2003 112 171 177 (Pubitemid 36869100)
9. Polymorphisms of folate and cobalamin metabolism. Rozen R, Homocysteine in Health and Disease. UK: Cambridge University Press, Carmel R, Jacobsen DW, 2001 259 270
10. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D'Ant M, Capasso R, Zappia V, Ruggiero G, Hepatology 2005 41 995 1003 10.1002/hep.20664 15834927 (Pubitemid 40593907)
11. Global epidemiology of hepatitis C virus infection. Finelli L, Alter MJ, Lancet Infect Dis 2005 5 558 56.7 10.1016/S1473-3099(05)70216-4 16122679 (Pubitemid 41196755)
12. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Negro F, Sanyal AJ, Liver Int 2009 29 uppl 2, 26 37
13. Liver steatosis and chronic hepatitis C: a spurious association? Fiore G, Fera G, Napoli N, Vella F, Schiraldi O, Eur J Gastroenterol Hepatol 1996 8 125e129
14. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG, J Hepatol 2004 40 484 490 15123364 (Pubitemid 38230851)
15. Steatosis affects chronic hepatitisC progression in a genotype specific way. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F, Gut 2004 53 406 12 10.1136/gut.2003.018770 14960525 (Pubitemid 38241339)
16. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D, Gut 2004 53 420 4 10.1136/gut.2002.009936 14960527 (Pubitemid 38241341)
17. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM, J Viral Hepat 2004 11 455 8 10.1111/j.1365-2893.2004.00528.x 15357652 (Pubitemid 39336228)
18. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Gruady SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA, Circulation 2004 109 551 6 10.1161/01.CIR.0000112379.88385.67 14757684 (Pubitemid 38168522)
19. Homeostasis model assessment: insulin resistance and -cell function from plasma fasting blood sugar and insulin concentration in man. Matthews DR, Hosker JP, Rudesnki AS, Naylor BA, Treacher DF, Turner RC, Diabetologia 1985 28 412 419 10.1007/BF00280883 3899825 (Pubitemid 15018832)
20. An evaluation of an automated homocysteine method on the Bayer ADVIA Centaur automated chemiluminescent system. Mindicino HJ, Carlsen J, Tewari P, Aagaard O, Zhang B, Conarpe C, Clin Lab 2002 48 493 496 12389709 (Pubitemid 35174966)
21. Estimation of the concentration of low-density lipoprotein in plasma, without the use of preparative ultracentrifuge. Friedewald WT, Levi RI, Fredrickson DS, Clin Chem 1992 21 1983 1985
22. A candidate genetic risk factor for vascular disease: A common mutation at the methylenetetrahydrofolate reductase locus. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. Nature Gen 1995 10 1 111 113 10.1038/ng0595-111
23. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N, J Thromb Thrombolysis 2004 17 199 205 15353918 (Pubitemid 39193987)
24. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y, Circulation 1997 95 2032 2036 9133512 (Pubitemid 27184270)
25. The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ, Atherosclerosis 2000 153 161 168 10.1016/S0021-9150(00) 00389-0 11058711
26. Methylenetetrahydrofolate reductase C677T polymorphismand liver fibrosis progression in patients with recurrent hepatitis C. Toniutto P, Fabris C, Falleti E, Cussigh A, Fontanini E, Bitetto D, Fornasiere E, Minisini R, De Feo T, Marangoni F, Pirisi M, Liver International 2007 273 263
27. Homocysteine levels and sustained virological response to pegylatedinterferon 2b plus ribavirin therapy for chronic hepatitis C:a prospective study. Borgia G, Gentile I, Fortunato G, Borrelli F, Borelli S, de Caterina M, Di Taranto MD, Simone M, Borgia F, Viola C, Reynaud L, Cerini R, Sacchetti L, Liver International 2008 248 252
28. Alheimer's Disease in Brazilian Elderly has a Relation With Homocysteine but not with MTHFR polymorphisms. da Silva VC, Ramos FJ, Freitas EM, de Brito-Marques PR, Cavalcanti MN, D'Almeida V, Cabral-Filho JE, Muniz MT, Arq Neuropsiquiatr 2006 64 4 941 945 10.1590/S0004-282X2006000600010 17221000 (Pubitemid 46120160)
29. C677T polymorphism of the MTHFR gene and variant haemoglobin: a study in newborns from Salvador,Bahia, Brazil. Couto FD, Adorno EV, Menezes JF, MouraNeto JP, dos Reis MG, Cad Saude Publica 2004 20 2 529 533 10.1590/S0102- 311X2004000200021 15073633
30. Steatosis and hepatitis C: mechanisms and significance for hepatic and extrahepatic disease. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP, Gastroenterology 2004 126 586 597 10.1053/j.gastro.2003.11.020 14762795 (Pubitemid 38182315)
31. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G, et al. JAMA 1997 277 1775 81 10.1001/jama.277.22. 1775 9178790 (Pubitemid 27247163)
32. Hyperhomocysteinemia: an independent risk factor for vascular disease. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I, N Engl J Med 1991 324 1149 55 10.1056/NEJM199104253241701 2011158
33. Hyperhomocysteinemia and venous thrombosis: a metaanalysis. Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM, Thromb Haemost 1998 80 874 7 9869152
34. Hyperhomocysteinemia, atherosclerosis and thrombosis. Cattaneo M, Thromb Haemost 1999 81 165 76 10063987 (Pubitemid 29078298)
35. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Melvin Hayden R, Suresh Tyagi C, Nutrition Journal 2004 3 4 10.1186/1475-2891-3-4 15134582 (Pubitemid 38751556)
36. Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Garcia-Tevijano ER, Berasain C, Rodriguez JA, Corrales FJ, Arias R, Martín-Duce A, Caballería J, Mato JM, Avila MA, Hypertension 2001 38 1217 21 10.1161/hy1101.099499 11711526 (Pubitemid 34252834)
37. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Torres L, Garcia-Trevijano E R, Rodriguez JA, Carretero MV, Bustos M, Fernández E, Eguinoa E, Mato JM, Avila MA, Biochim Biophys Acta 1999 1455 12 22 10524225 (Pubitemid 29397485)
38. Intermediate homocysteinemia:a thermolabile variant of methylenetetrahydrofolate reductase. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G, AmJ Hum Genet 1988 43 414 421
39. Methionine metabolism in mammals. The methionine-sparing effect of cystine. Finkelstein JD, Martin JJ, Harris BJ, J Biol Chem 1988 263 11750 11754 3403552
40. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, Loscalzo J, JBiol Chem 1997 272 17012 17017 10.1074/jbc.272.27.17012 (Pubitemid 27289806)
41. Characterization of the stress-inducing effects of homocysteine. Outinen PA, Sood SK, Liaw PC, Sarge KD, Maeda N, Hirsh J, Ribau J, Podor TJ, Weitz JI, Austin RC, Biochem J 1998 332 213 221 9576870 (Pubitemid 28239337)
42. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, Faraci FM, Lentz SR, Arterioscler Thromb Vasc Biol 2002 22 1996 2002 10.1161/01.ATV.0000041629.92741.DC 12482825 (Pubitemid 36025205)
43. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit andman. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D, J Clin Invest 1989 84 1086 1095 10.1172/JCI114271 2794046 (Pubitemid 19247577)
44. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, Austin RC, J Clin Invest 2001 107 1263 73 10.1172/JCI11596 11375416 (Pubitemid 32494543)
45. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccal G, Lotteau V, J Virol 2002 76 6919 6928 10.1128/JVI.76.14.6919-6928.2002 12072493 (Pubitemid 41246207)
46. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX, Proc Natl Acad Sci USA 1999 96 12766 12771 10.1073/pnas.96.22.12766 10535997 (Pubitemid 29513577)
47. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, Roitelman J, Barbaras R, Graber P, Ghersa P, Smolarsky M, Funaro A, Malavasi F, Larrey D, Coste J, Fabre JM, Sa-Cunha A, Maurel P, J Hepatol 2007 46 411 419 10.1016/j.jhep.2006.09.024 17156886 (Pubitemid 46201721)